Lat-Y136F

品系全名

C57BL/6JSmo-Latem1(Y136F)Smoc

目录号

NM-KI-200249

品系状态

活体

导出PDF

基因信息

基因名
Lat

品系描述

将Lat中第136位氨基酸由Y变为F,建立Lat点突变小鼠模型。
应用领域:罕见病模型--IgG4相关性疾病

疾病预测

IgG4相关性疾病
Igg4-Related Disease

验证数据

image.png

Fig 1. Spleen (left) and mesenteric lymph nodes (right) from 8-week-old wild-type and Lat-Y136F mice.

image.png

Fig 2. Flow cytometry analysis of different subsets of T cells across tissues in homozygous Lat-Y136F mice in mesenteric lymph nodes (MLN) (n=3).

image.png

Fig 3. Flow cytometry analysis of different subsets of T cells across tissues in homozygous Lat-Y136F mice in peripheral blood (n=3).

image.png

Fig 4. Flow cytometry analysis of different subsets of T cells across tissues in homozygous Lat-Y136F mice in spleen (n=3).

image.png

Fig 5. Flow cytometry analysis of different subsets of T cells across tissues in homozygous Lat-Y136F mice in thymus (n=3).

image.png

Fig 6. Serum IgG1 and IgE levels in homozygous Lat-Y136F mice (n=3-5).

image.png

Fig 7. Histopathological analysis across organs in homozygous Lat-Y136F mice(n=3-4). Scale bar=100 μm; magnification,  200×.

image.png

Fig 8. Serum IgG1 level and body weight post 3 weeks treatment in 4/7-week old homozygous Lat-Y136F mice (n=5).

image.png

Fig 9. Wet weight and photos of spleen and mesenteric lymph nodes (MLN) upon prednisolone treatment in 7-week old homozygous Lat-Y136F mice (n=5).

image.png

Fig. 10 Histopathology changes upon prednisolone treatment. Representative histopathological appearance of kidney and pancreas in 7-week-old prednisolone-treated and saline-treated control mice. Red arrows indicate inflammatory lesions and black arrows indicate fibrosis in the kidney and pancreas of C57 control mice, saline- or prednisolone-treated Lat-Y136F mice (n=5). Data are presented as mean and ± SEM. Scale bar=100 μm; magnification, 200×.


你也可能感兴趣

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

查看

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

查看

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

查看